A tissue-adhesive F127 hydrogel delivers antioxidative copper-selenide nanoparticles for the treatment of dry eye disease

Acta Biomater. 2024 Feb:175:353-368. doi: 10.1016/j.actbio.2023.12.021. Epub 2023 Dec 16.

Abstract

Dry eye disease (DED) is currently the most prevalent condition seen in ophthalmology outpatient clinics, representing a significant public health issue. The onset and progression of DED are closely associated with oxidative stress-induced inflammation and damage. To address this, an aldehyde-functionalized F127 (AF127) hydrogel eye drop delivering multifunctional antioxidant Cu2-xSe nanoparticles (Cu2-xSe NPs) was designed. The research findings revealed that the Cu2-xSe nanoparticles exhibit unexpected capabilities in acting as superoxide dismutase and glutathione peroxidase. Additionally, Cu2-xSe NPs possess remarkable efficacy in scavenging reactive oxygen species (ROS) and mitigating oxidative damage. Cu2-xSe NPs displayed promising therapeutic effects in a mouse model of dry eye. Detailed investigation revealed that the nanoparticles exert antioxidant, anti-apoptotic, and inflammation-mitigating effects by modulating the NRF2 and p38 MAPK signalling pathways. The AF127 hydrogel eye drops exhibit good adherence to the ocular surface through the formation of Schiff-base bonds. These findings suggest that incorporating antioxidant Cu2-xSe nanoparticles into a tissue-adhesive hydrogel could present a highly effective therapeutic strategy for treating dry eye disease and other disorders associated with reactive oxygen species. STATEMENT OF SIGNIFICANCE: A new formulation for therapeutic eye drops to be used in the treatment of dry eye disease (DED) was developed. The formulation combines copper-selenium nanoparticles (Cu2-xSe NPs) with aldehyde-functionalized Pluronic F127 (AF127). This is the first study to directly examine the effects of Cu2-xSe NPs in ophthalmology. The NPs exhibited antioxidant capabilities and enzyme-like properties. They effectively eliminated reactive oxygen species (ROS) and inhibited apoptosis through the NRF2 and p38 MAPK signalling pathways. Additionally, the AF127 hydrogel enhanced tissue adhesion by forming Schiff-base links. In mouse model of DED, the Cu2-xSe NPs@AF127 eye drops demonstrated remarkable efficacy in alleviating symptoms of DED. These findings indicate the potential of Cu2-xSe NPs as a readily available and user-friendly medication for the management of DED.

Keywords: Antioxidant; Cu(2−x)Se nanoparticles; Dry eye disease; F127; Ocular adhesive.

MeSH terms

  • Aldehydes
  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Copper / chemistry
  • Copper / pharmacology
  • Dry Eye Syndromes* / drug therapy
  • Hydrogels / pharmacology
  • Hydrogels / therapeutic use
  • Inflammation / drug therapy
  • Mice
  • NF-E2-Related Factor 2 / therapeutic use
  • Nanoparticles* / chemistry
  • Nanoparticles* / therapeutic use
  • Ophthalmic Solutions / pharmacology
  • Polyethylenes*
  • Polypropylenes*
  • Reactive Oxygen Species
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Antioxidants
  • Copper
  • Reactive Oxygen Species
  • UCON 50-HB-5100
  • Hydrogels
  • NF-E2-Related Factor 2
  • Ophthalmic Solutions
  • Aldehydes
  • p38 Mitogen-Activated Protein Kinases
  • Polyethylenes
  • Polypropylenes